The DOI matches its Crossref record.
Determinants for Sustained Hbeag Response to Lamivudine Therapy
Abstract
There are inconsistent data on the durability of hepatitis B e antigen (HBeAg) seroconversion after lamivudine is discontinued. The aim of this study was to examine the determinants for sustained HBeAg response to lamivudine therapy. Both host and viral factors as well as the drug factor were compared between 43 patients with sustained HBeAg response and 39 patients whose response was not sustained. All of them received a mean period of 16 months (range, 3–55 months) lamivudine therapy and had achieved complete response (HBeAg seroconversion plus HBV DNA seroclearance by hybrid capture assay and normal alanine aminotransferase [ALT]) and were followed–up for a mean period of 44 months (range, 12–88 months). Stepwise logistic regression model was used to estimate the sustained response on the presence of the following variables: age; gender; pretherapy ALT; total bilirubin and HBV DNA levels; time to HBeAg seroconversion; additional lamivudine treatment after HBeAg seroconversion; total duration of treatment; hepatitis activity index scores; periportal, intralobular, and portal inflammation and fibrosis scores; scores excluding fibrosis; status of precore mutation; basal core promoter mutation; and genotype. The results showed that genotype (OR, 5.922; 95% CI, 1.611–21.768; P = .007), age (OR, 0.943; 95% CI, 0.891–0.997; P = .040), and additional treatment (OR, 1.097; 95% CI, 1.028–1.171; P = .005) were independent factors to sustained HBeAg response. Further categorical analysis disclosed that patients with genotype B, age ≤36 years, and additional lamivudine treatment over 8 months have higher sustained response. In conclusion, HBV genotype, age, and additional treatment are the major determinants for the sustained HBeAg response to lamivudine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
Liaw, Y.-F., Kao, J.-H., Piratvisuth, T., Chan, H. L. Y., Chien, R.-N., Liu, C.-J., Gane, E., Locarnini, S., Lim, S.-G., Han, K.-H., et al. (2012) · Hepatology International · doi:10.1007/s12072-012-9365-4 · Cited by 1,038
Self-citationAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
Liaw, Y.-F., Leung, N., Kao, J.-H., Piratvisuth, T., Gane, E., Han, K.-H., Guan, R., Lau, G. K. K., Locarnini, S., & for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver (2008) · Hepatology International · doi:10.1007/s12072-008-9080-3 · Cited by 867
Self-citation
Metadata
- Authors
- Chien, R.-N., Yeh, C.-T., Tsai, S.-L., Chu, C.-M., & Liaw, Y.-F.
- Venue
- Hepatology
- Published
- 2003-11
- Volume
- 38
- Issue
- 5
- Pages
- 1267-1273
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2089136108
- Cited by
- 214
- References
- 0
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Determinants for Sustained Hbeag Response to Lamivudine Therapy. https://app.cochat.ai/papers/10.1053/jhep.2003.50458
- The paper
- Chien, R.-N., Yeh, C.-T., Tsai, S.-L., Chu, C.-M., & Liaw, Y.-F. (2003). Determinants for Sustained Hbeag Response to Lamivudine Therapy. Hepatology. https://doi.org/10.1053/jhep.2003.50458
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.